Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Antibodies to the prefusion conformation of the RSV F glycoprotein neutralize natural infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O'Brien, K. L., Roca, A., Wright, P. F., Bruce, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60206-1 · Cited by 2,773
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C., & Walsh, E. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043951 · Cited by 2,226
Risk of Primary Infection and Reinfection With Respiratory Syncytial Virus
Glezen, W. P. (1986) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1986.02140200053026 · Cited by 1,527
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Self-citationStructure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883
Self-citationRates of hospitalization for respiratory syncytial virus infection among children in Medicaid
Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000) · The Journal of Pediatrics · doi:10.1067/mpd.2000.110531 · Cited by 688
Zhang, L., Peeples, M. E., Boucher, R. C., Collins, P. L., & Pickles, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5654-5666.2002 · Cited by 581
Self-citationMcLellan, J. S., Yang, Y., Graham, B. S., & Kwong, P. D. (2011) · Journal of Virology · doi:10.1128/jvi.00555-11 · Cited by 436
Self-citationPrimary respiratory syncytial virus infection in mice
Graham, B. S., Perkins, M. D., Wright, P. F., & Karzon, D. T. (1988) · Journal of Medical Virology · doi:10.1002/jmv.1890260207 · Cited by 393
Self-citation
Cited by
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
Walsh, E. E., Pérez Marc, G., Zareba, A. M., Falsey, A. R., Jiang, Q., Patton, M., Polack, F. P., Llapur, C., Doreski, P. A., Ilangovan, K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213836 · Cited by 668
Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment
Griffiths, C., Drews, S. J., & Marchant, D. J. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-16 · Cited by 586
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults
Wilson, E., Goswami, J., Baqui, A. H., Doreski, P. A., Perez-Marc, G., Zaman, K., Monroy, J., Duncan, C. J. A., Ujiie, M., Rämet, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307079 · Cited by 500
Mazur, N. I., Higgins, D., Nunes, M. C., Melero, J. A., Langedijk, A. C., Horsley, N., Buchholz, U. J., Openshaw, P. J., McLellan, J. S., Englund, J. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30292-5 · Cited by 457
Self-citationMarcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E., Benhaim, M., Ravichandran, R., Carter, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.046 · Cited by 448
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Mazur, N. I., Terstappen, J., Baral, R., Bardají, A., Beutels, P., Buchholz, U. J., Cohen, C., Crowe, J. E., Cutland, C. L., Eckert, L., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00291-2 · Cited by 420
Self-citationRespiratory syncytial virus entry and how to block it
Battles, M. B., & McLellan, J. S. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0149-x · Cited by 402
Self-citationA highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Zhu, Q., McLellan, J. S., Kallewaard, N. L., Ulbrandt, N. D., Palaszynski, S., Zhang, J., Moldt, B., Khan, A., Svabek, C., McAuliffe, J. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj1928 · Cited by 362
Self-citationThe role of vaccines in preventing bacterial antimicrobial resistance
Jansen, K. U., Knirsch, C., & Anderson, A. S. (2018) · Nature Medicine · doi:10.1038/nm.4465 · Cited by 355
Respiratory syncytial virus infection in adults
Nam, H. H., & Ison, M. G. (2019) · BMJ · doi:10.1136/bmj.l5021 · Cited by 332
A proof of concept for structure-based vaccine design targeting RSV in humans
Crank, M. C., Ruckwardt, T. J., Chen, M., Morabito, K. M., Phung, E., Costner, P. J., Holman, L. A., Hickman, S. P., Berkowitz, N. M., Gordon, I. J., et al. (2019) · Science · doi:10.1126/science.aav9033 · Cited by 333
Self-citationMosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses
Kanekiyo, M., Joyce, M. G., Gillespie, R. A., Gallagher, J. R., Andrews, S. F., Yassine, H. M., Wheatley, A. K., Fisher, B. E., Ambrozak, D. R., Creanga, A., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0305-x · Cited by 301
Self-citationFc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
van Erp, E. A., Luytjes, W., Ferwerda, G., & van Kasteren, P. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00548 · Cited by 281
Antibodies to combat viral infections: development strategies and progress
Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S., & Perez, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 279
Structure-Based Vaccine Antigen Design
Graham, B. S., Gilman, M. S. A., & McLellan, J. S. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-121217-094234 · Cited by 234
“Protein engineering efforts resulted in authentic stabilized pre-F trimers (41–44) that preserved the key epitopes associated with most neutralizing activity in human sera (45).”
BackgroundSelf-citationTregoning, J. S., Brown, E. S., Cheeseman, H. M., Flight, K. E., Higham, S. L., Lemm, N.-M., Pierce, B. F., Stirling, D. C., Wang, Z., & Pollock, K. M. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13517 · Cited by 224
De novo protein design enables the precise induction of RSV-neutralizing antibodies
Sesterhenn, F., Yang, C., Bonet, J., Cramer, J. T., Wen, X., Wang, Y., Chiang, C.-I., Abriata, L. A., Kucharska, I., Castoro, G., et al. (2020) · Science · doi:10.1126/science.aay5051 · Cited by 191
Advances in RSV vaccine research and development – A global agenda
Higgins, D., Trujillo, C., & Keech, C. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.109 · Cited by 202
Vaccine development for respiratory syncytial virus
Graham, B. S. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.03.012 · Cited by 195
Self-citationEspeseth, A. S., Cejas, P. J., Citron, M. P., Wang, D., DiStefano, D. J., Callahan, C., Donnell, G. O., Galli, J. D., Swoyer, R., Touch, S., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0163-z · Cited by 190
“Although epitopes targeted by neutralizing monoclonal antibodies exist on both conformations, characterization of the natural human immune response to RSV infection revealed that most RSV-neutralizing antibodies bind the prefusion conformation of the F protein.(4,5) The elucidation of the crystal structure of RSV F pr…”
BackgroundImmunological Lessons from Respiratory Syncytial Virus Vaccine Development
Ruckwardt, T. J., Morabito, K. M., & Graham, B. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.007 · Cited by 185
Self-citationIterative structure-based improvement of a fusion-glycoprotein vaccine against RSV
Joyce, M. G., Zhang, B., Ou, L., Chen, M., Chuang, G.-Y., Druz, A., Kong, W.-P., Lai, Y.-T., Rundlet, E. J., Tsybovsky, Y., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3267 · Cited by 167
Self-citationAliprantis, A. O., Shaw, C. A., Griffin, P., Farinola, N., Railkar, R. A., Cao, X., Liu, W., Sachs, J. R., Swenson, C. J., Lee, H., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1829899 · Cited by 149
“Studies of humoral immune response to natural RSV infection have shown that the majority of the human antibody response targets the prefusion conformation.(15,16) The advent of structure-based design methods to stabilize the prefusion”
BackgroundMousa, J. J., Kose, N., Matta, P., Gilchuk, P., & Crowe, J. E. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.271 · Cited by 111
“Recent experiments suggested a dominant role for epitopes in the pre-fusion conformation of RSV F in the induction of serum neutralizing antibodies, particularly a major role for antigenic site Ø in immunogenicity 15 .”
Bottom-up de novo design of functional proteins with complex structural features
Yang, C., Sesterhenn, F., Bonet, J., van Aalen, E. A., Scheller, L., Abriata, L. A., Cramer, J. T., Wen, X., Rosset, S., Georgeon, S., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00699-x · Cited by 84
New Vaccine Design and Delivery Technologies
Kanekiyo, M., Ellis, D., & King, N. P. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy745 · Cited by 69
“This type of conformational heterogeneity can be problematic if the metastable prefusion state is desired antigenically [22, 26, 27] , and it can be exaggerated when antigens are recombinantly expressed and purified in isolation.”
BackgroundSelf-citationKulkarni, P. S., Hurwitz, J. L., Simões, E. A. F., & Piedra, P. A. (2018) · Viral Immunology · doi:10.1089/vim.2017.0147 · Cited by 53
Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Rossey, I., & Saelens, X. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1675520 · Cited by 32
“predominantly attributable to prefusion F-specific antibodies [23,24].”
BackgroundKherfan, T., & Sallam, M. (2023) · Vaccines · doi:10.3390/vaccines11081386 · Cited by 26
Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes
Fedechkin, S. O., George, N. L., Nuñez Castrejon, A. M., Dillen, J. R., Kauvar, L. M., & DuBois, R. M. (2020) · Journal of Virology · doi:10.1128/jvi.01879-19 · Cited by 26
A general computational design strategy for stabilizing viral class I fusion proteins
Gonzalez, K. J., Huang, J., Criado, M. F., Banerjee, A., Tompkins, S. M., Mousa, J. J., & Strauch, E.-M. (2024) · Nature Communications · doi:10.1038/s41467-024-45480-z · Cited by 20
Metadata
- Authors
- Ngwuta, J. O., Chen, M., Modjarrad, K., Joyce, M. G., Kanekiyo, M., Kumar, A., Yassine, H. M., Moin, S. M., Killikelly, A. M., Chuang, G.-Y., Druz, A., Georgiev, I. S., Rundlet, E. J., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Nason, M. C., Capella, C., Peeples, M. E., Ledgerwood, J. E., McLellan, J. S., Kwong, P. D., & Graham, B. S.
- Venue
- Science Translational Medicine
- Published
- 2015-10-14
- Volume
- 7
- Issue
- 309
- Pages
- 309ra162-309ra162
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2270869679
- Cited by
- 431
- References
- 26
- FWCI
- 22.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.